Ravulizumab-cwvz (Intravenous)
Medically reviewed by Drugs.com. Last updated on May 1, 2022.
Warning: Serious Meningococcal InfectionsLife-threatening meningococcal infections/sepsis have occurred in patients treated with ravulizumab-cwvz. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies. Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of ravulizumab-cwvz, unless the risks of delaying ravulizumab-cwvz therapy outweigh the risk of developing a meningococcal infection. Vaccination reduces, but does not eliminate, the risk of meningococcal infections Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected. Ravulizumab-cwvz is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the ravulizumab-cwvz REMS, prescribers must enroll in the program .
Commonly used brand name(s)
In the U.S.
- Ultomiris
Available Dosage Forms:
- Solution
Therapeutic Class: Blood Modifier Agent
Pharmacologic Class: Ravulizumab
Uses for ravulizumab-cwvz
Ravulizumab-cwvz injection is used to treat a type of blood disease called paroxysmal nocturnal hemoglobinuria (PNH). Ravulizumab-cwvz helps reduce red blood cell destruction or breakdown (hemolysis) in patients with PNH.
Ravulizumab-cwvz injection is also used to treat atypical hemolytic uremic syndrome (aHUS) in adults and children.
Ravulizumab-cwvz injection is also used to treat a nerve and muscle problem called generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody positive.
Ravulizumab-cwvz injection is a monoclonal antibody that works on the immune system.
Ravulizumab-cwvz is available only under a restricted distribution program called Ultomiris® REMS (Risk Evaluation and Mitigation Strategy) Program.
Before using ravulizumab-cwvz
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For ravulizumab-cwvz, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to ravulizumab-cwvz or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of ravulizumab-cwvz injection to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) in children 1 month of age and older. However, safety and efficacy have not been established to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) in children younger than 1 month of age or to treat generalized myasthenia gravis (gMG) in children.
Geriatric
Appropriate studies pe..
